Role of brain imaging in early parkinsonism

BMJ

Volumn 342, Issue 7795, 2011, Pages 495-498

  Breen, David P ^a   Rowe, James B ^b   Barker, Roger A ^a  

^a UNIVERSITY OF CAMBRIDGE   (United Kingdom)

^b UNIVERSITY OF CAMBRIDGE   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIDEPRESSANT AGENT; CALCIUM CHANNEL BLOCKING AGENT; LITHIUM; METHYLDOPA; METOCLOPRAMIDE; PROCHLORPERAZINE; ROPINIROLE; VALPROIC ACID;

AGED; ARTICLE; BRADYKINESIA; CASE REPORT; CLINICAL FEATURE; DIAGNOSTIC TEST ACCURACY STUDY; DIFFERENTIAL DIAGNOSIS; EARLY DIAGNOSIS; FUNCTIONAL MAGNETIC RESONANCE IMAGING; HAND MOVEMENT; HUMAN; MALE; NEUROIMAGING; OUTCOME ASSESSMENT; PARKINSONISM; POSITRON EMISSION TOMOGRAPHY; PRIORITY JOURNAL; SINGLE PHOTON EMISSION COMPUTER TOMOGRAPHY; TREMOR; DIAGNOSTIC IMAGING; METHODOLOGY; NUCLEAR MAGNETIC RESONANCE IMAGING; PARKINSON DISEASE;

AGED; DIAGNOSIS, DIFFERENTIAL; DIAGNOSTIC IMAGING; HUMANS; MAGNETIC RESONANCE IMAGING; MALE; PARKINSON DISEASE; POSITRON-EMISSION TOMOGRAPHY;

EID: 79952051386     PISSN: None     EISSN: 17561833     Source Type: Journal    
DOI: 10.1136/bmj.d638     Document Type: Article

References (21)

1. Hughes AJ, Daniel SE, Ben-Shlomo Y, Lees AJ. The accuracy of diagnosis of parkinsonian syndromes in a specialist movement disorder service. Brain 2002;125:861-70. [Abstract/FREE Full text]
2. Gibb WR, Lees AJ. The relevance of the Lewy body to the pathogenesis of idiopathic Parkinson's disease. J Neurol Neurosurg Psychiatr 1988;51:745-52. [Abstract/FREE Full text]
3. The National Collaborating Centre for Chronic Conditions. Parkinson's disease: national clinical guideline for diagnosis and management in primary and secondary care. London: Royal College of Physicians, 2006. (Available at www.nice.org.uk/CG035.)
4. Scottish Intercollegiate Guidelines Network. Diagnosis and pharmacological management of Parkinson's disease. Edinburgh: SIGN, 2010. (SIGN publication No 113). www.sign.ac.uk/guidelines/fulltext/113/index.html
5. Vlaar AMM, van Kroonenburgh MJPG, Kessels AGH, Weber WEJ. Meta-analysis of the literature on diagnostic accuracy of SPECT in parkinsonian syndromes. BMC Neurology 2007;7:27. [CrossRef] [Medline]
6. Speigel J, Hellwig D, Samnick S, Jost W, Mollers MO, Kirsch C-M, et al. Striatal FP-CIT uptake differs in the subtypes of early Parkinson's disease. J Neural Transm 2007;114:331-5. [CrossRef] [Medline] [Web of Science]
7. Seibyl JP, Marek K, Sheff K, Baldwin RM, Zoghbi S, Zea-Ponce Y, et al. Test/retest reproducibility of iodine-123-βCIT SPECT brain measurement of dopamine transporters in Parkinson's patients. J Nucl Med 1997;38:1453-9. [Abstract/FREE Full text]
8. Booij J, Habraken JB, Bergmens P, Tissingh G, Winogrodzka A, Wolters EC, et al. Imaging of dopamine transporters with iodine-123-FP-CIT SPECT in healthy controls and patients with Parkinson's disease. J Nucl Med 1998;39:1879-84. [Abstract/FREE Full text]
9. Kagi G, Bhatia KP, Tolosa E. The role of DAT-SPECT in movement disorders. J Neurol Neursurg Psychiatr 2010;81:5-12. [CrossRef]
10. Oba H, Yagishita A, Terada H, Barkovich AJ, Kutomi K, Yamauchi T, et al . New and reliable MRI diagnosis for progressive supranuclear palsy. Neurology 2005;64:2050-5. [Abstract/FREE Full text]
11. Yekhlef F, Ballan G, Macia F, Delmer O, Sourgen C, Tison F. Routine MRI for the differential diagnosis of Parkinson's disease, MSA, PSP, and CBD. J Neural Transm 2003;110:151-69. [CrossRef] [Medline] [Web of Science]
12. Lewis SJG, Dove A, Robbins TW, Barker RA, Owen AM. Cognitive impairments in early Parkinson's disease are accompanied by reductions in activity in frontostriatal neural circuitry. J Neurosci 2003;23:6351-6. [Abstract/FREE Full text]
13. Rowe JB, Hughes L, Ghosh BCP, Eckstein D, Williams-Gray CH, Fallon S, et al. Parkinson's disease and dopaminergic therapy - differential effects on movement, reward and cognition. Brain 2008;131:2094-105. [Abstract/FREE Full text]
14. Hely MA, Reid WG, Adena MA, Halliday GM, Morris JG. The Sydney multicentre study of Parkinson's disease: the inevitability of dementia at 20 years. Mov Disord 2008;23:837-44. [CrossRef] [Medline] [Web of Science]
15. Buter TC, van der Hout A, Matthews FE, Larsen JP, Brayne C, Aarsland D. Dementia and survival in Parkinson's disease: a 12-year population study. Neurology 2008;70:1017-22. [Abstract/FREE Full text]
16. Bohnen NI, Minoshima S, Giordani B, Frey KA, Kuhl DE. Motor correlates of occipital glucose hypometabolism in Parkinson's disease without dementia. Neurology 1999;52:541-6. [Abstract/FREE Full text]
17. Hu MT, Taylor-Robinson SD, Chaudhuri KR, Bell JD, Labbe C, Cunningham VJ, et al. Cortical dysfunction in non-demented Parkinson's disease patients: a combined (31)P-MRS and (18)FDG-PET study. Brain 2000;123:340-52. [Abstract/FREE Full text]
18. Edison P, Rowe CC, Rinne JO, Ng S, Ahmed I, Kemppalnen N, et al. Amyloid load in Parkinson's disease dementia and Lewy body dementia measured with [11C] PIB positron emission tomography . J Neurol Neurosurg Psychiatr 2009;79:1331-8. [CrossRef] [Web of Science]
19. Ouchi Y, Yoshikawa E, Sekine Y, Futatsubashi M, Kanno T, Ogusu T, et al. Microglial activation and dopamine terminal loss in early Parkinson's disease. Ann Neurol 2005;57:168-75. [CrossRef] [Medline] [Web of Science]
20. Brooks DJ. Technology insight: imaging neurodegeneration in Parkinson's disease. Nature Clin Pract Neurol 2008;4:267-77. [CrossRef]
21. Tang CC, Poston KL, Eckert T, Feigin A, Frucht S, Gudesblatt M, et al. Differential diagnosis of parkinsonism: a metabolic imaging study using pattern analysis. Lancet Neurol 2010;9:149-58. [CrossRef] [Medline] [Web of Science]